Pharmacokinetic and tumour studies of aloin (a natural anthraquinone) on mice bearing solid ehrlich carcinoma

Journal of Tumor Marker Oncology

Volumn 12, Issue 2, 1997, Pages 127-133

  Fahim, Fawzia A ^a   Esmat, Amr Y ^a   Mady, Essam A ^a   Amin, Magda A ^a  

^a Ain Shams University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0010054745     PISSN: 08863849     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Abbott, B.J.; Leiter, J.L.; Hartwell, R.E.; Rerdre.J. and Schepartz, A.S Screening data from the cancer chemotherapy national service center screening laboratory. XXX Plant extracts. Cancer Res., 27 (suppl): 190, 1967.
2. Behren's-Karber, G. In: "Chemotherapy of neoplastic diseases", Seilei, G. Ckhardt, S.T. and Nemeth, L.(eds), p37, Budapest, The publishing house of Hungarian academy, 1970.
3. Bissery, M.C.; Guenard, D.; Gueritte Voegelien, F. and Lavelle, F. Experimental antitumour activity of taxotera, a taxol analog. Cancer Res., 51:4845,1991
4. Buc-Calderon, P.; Praet, M.; Ruysschaert, Ü.M. and Roberfroid, M. Increasing therapeutic effect and reducing toxicity of doxorubicin by Nacyldehydroalanines. Eur. J. Cancer Clin. Oncol., 25: 679, 1989
5. Collins, Ü.M.; Zaharko, D.S.; Dedrick, R.L and Chabner, B.A. Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treatment Rep., 70: 73, 1986
6. DiMarco, A.; Gaetani, M. And Scarpinato, B. Adriamycin (NSC-123,127): A new antibiotic with antitumour activity. Cancer chemother. Rep., 53 (1): 33, 1969
7. Fahim, FA; Abdu Allah, N.M.; Aboul Ela, F. and Esmat, A.Y. Aloin: a natural anthraquinone with potential antitumour activity.J. Tumour Mark. Oncol., 8(1): 27, 1993a
8. Fahim, F.A.; Abdu Allah, N.M. and Esmat, A.Y. Some metabolic aspects in normal and tumour bearing mice treated with a natural anthraquinone. J. Tumour Mark. Oncol.,8(1) 35, 1993b
9. Freireich, E.J.; Gehan, E.A.; Rail, O.P. and Schmidit, L.H. Quantitative comparison of toxicity of anticancer agents in mouse, rats, dogs, monkeys and man. Cancer Chemother. Rep.,50: 219, 1986
10. Geran, R.T.; Greenberg, N.H.; MacDonald, M.M. and Schumacher, A.M. Protocols of screening chemical agents and natural products against animal tumours and other biological systems.Cancer Chemother. Rep. 3 (3): 1,1972
11. Keiji, Y; Akihiro, F.; Masafumi, A. and Takeki, O. Antitumour activity of 2-deoxy-2-methylidene cytidine, a new 2-deoxycytidine derivative. Cancer Res., 51: 2319, 1991
12. Maaike, B.; Van, H.; Win, J.F. and Vander, V. Comparative pharmacokinetics of cisplatin and three analogues in mice and human. Cancer Res., 47 (1): 6282, 1987
13. Mayer, F.H.; Jauetz, E. and Coldfien, A. Adrenergic blocking drugs in review of medical pharmacology, Fex.G. and Oliver.R. (eds), 7th edn, p.95 California, Pergamon Press, 1990
14. MiloGibaldi, M.Y. In: Biopharmaceutics and pharmacokinetics, Feng, P.H. (ed), 4th edn, p. 295, New York, Laurie Prescott, 1991
15. Sellei, C.; Hardet, E. and Nemeth, L. In: Chemotherapy of neoplastic diseases, p. 35, Budapest, Academia Kid publishing house of the Hungarain academy of science, 1970
16. Trease, B.N and Evans, V.K. In: Text book of pharmacognosy. Gupata. C.M. (ed), 3rd edn, p.530, Philadelphia, Lippincott Co, 1972
17. Woolly, P.V. and Schein, P.S. Clinical pharmacology and phase I trial design. Methods Cancer Res., 17: 177,1989
18. Yasuka, I.H.; Hisayuki, T. and Yoshio, T. Fluorophotometry of barbaloin in Aloe. Chem. Pharm. Bull., 32 (12): 4946, 1984